Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines, has announced its participation in four upcoming investor conferences in September 2025. President and CEO Bo Cumbo will participate in fireside chats at the Citi Biopharma Back to School Conference (Sept 2), Cantor Global Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 8), and Baird Global Healthcare Conference (Sept 9).
All fireside chat sessions will be available via webcast on the company's investor relations website, with replays archived for 90 days. Management will also conduct one-on-one meetings with institutional investors during each conference.
Solid Biosciences (Nasdaq: SLDB), una società life sciences focalizzata sullo sviluppo di terapie genetiche di precisione, ha annunciato la sua partecipazione a quattro conferenze per investitori previste per settembre 2025. Il presidente e CEO Bo Cumbo prenderà parte a fireside chat al Citi Biopharma Back to School Conference (2 set), al Cantor Global Healthcare Conference (4 set), all'H.C. Wainwright Global Investment Conference (8 set) e al Baird Global Healthcare Conference (9 set).
Tutte le sessioni saranno trasmesse via webcast sul sito IR della società, con le registrazioni disponibili in archivio per 90 giorni. La direzione terrà inoltre incontri one-to-one con investitori istituzionali durante ciascuna conferenza.
Solid Biosciences (Nasdaq: SLDB), una compañía de ciencias de la vida centrada en desarrollar medicinas genéticas de precisión, ha anunciado su participación en cuatro conferencias para inversores en septiembre de 2025. El presidente y CEO Bo Cumbo participará en charlas informales en el Citi Biopharma Back to School Conference (2 de sept.), el Cantor Global Healthcare Conference (4 de sept.), el H.C. Wainwright Global Investment Conference (8 de sept.) y el Baird Global Healthcare Conference (9 de sept.).
Todas las charlas se emitirán por webcast en el sitio web de relaciones con inversores de la compañía, y las repeticiones estarán archivadas durante 90 días. La dirección también mantendrá reuniones individuales con inversores institucionales en cada conferencia.
Solid Biosciences (Nasdaq: SLDB), 정밀 유전자 치료제 개발에 주력하는 생명과학 기업이 2025년 9월 개최되는 4개의 투자자 컨퍼런스에 참가한다고 발표했습니다. 사장 겸 CEO인 보 검보(Bo Cumbo)가 Citi Biopharma Back to School Conference(9월 2일), Cantor Global Healthcare Conference(9월 4일), H.C. Wainwright Global Investment Conference(9월 8일), Baird Global Healthcare Conference(9월 9일)에서 파이어사이드 챗에 참여합니다.
모든 파이어사이드 챗은 회사 투자자 관계 웹사이트를 통해 웨비캐스트로 제공되며, 다시보기는 90일 동안 아카이브됩니다. 경영진은 각 컨퍼런스 기간 동안 기관 투자자들과 일대일 미팅도 진행할 예정입니다.
Solid Biosciences (Nasdaq: SLDB), une société des sciences de la vie spécialisée dans le développement de médicaments génétiques de précision, a annoncé sa participation à quatre conférences investisseurs prévues en septembre 2025. Le président-directeur général Bo Cumbo participera à des discussions informelles lors du Citi Biopharma Back to School Conference (2 sept.), du Cantor Global Healthcare Conference (4 sept.), du H.C. Wainwright Global Investment Conference (8 sept.) et du Baird Global Healthcare Conference (9 sept.).
Toutes les sessions seront diffusées en webcast sur le site relations investisseurs de la société, avec les replays archivés pendant 90 jours. La direction tiendra également des rendez-vous individuels avec des investisseurs institutionnels lors de chaque conférence.
Solid Biosciences (Nasdaq: SLDB), ein Life-Sciences-Unternehmen, das sich auf die Entwicklung präziser Gentherapien konzentriert, hat seine Teilnahme an vier bevorstehenden Investorenkonferenzen im September 2025 angekündigt. Präsident und CEO Bo Cumbo wird an Fireside-Chats beim Citi Biopharma Back to School Conference (2. Sept.), Cantor Global Healthcare Conference (4. Sept.), H.C. Wainwright Global Investment Conference (8. Sept.) und Baird Global Healthcare Conference (9. Sept.) teilnehmen.
Alle Fireside-Chats werden per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein; Wiederholungen werden 90 Tage archiviert. Das Management wird während jeder Konferenz zudem Einzelgespräche mit institutionellen Investoren führen.
- None.
- None.
CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- 2025 Citi Biopharma Back to School Conference
Bo Cumbo, President and CEO, will participate in a fireside chat on Tuesday, September 2, 2025, at 1:45 p.m. ET. A live webcast will be available by clicking here.
- Cantor Global Healthcare Conference
Mr. Cumbo will participate in a fireside chat on Thursday, September 4, 2025, at 3:20 p.m. ET. A live webcast will be available by clicking here.
- H.C. Wainwright 27th Annual Global Investment Conference
Mr. Cumbo will participate in a fireside chat on Monday, September 8, 2025, at 9:00 a.m. ET. A live webcast will be available by clicking here.
- 2025 Baird Global Healthcare Conference
Mr. Cumbo will participate in a fireside chat on Tuesday September 9, 2025, at 3:10 p.m. ET. A live webcast will be available by clicking here.
Each fireside chat webcast will be available on the Events page of the Investors section of the Company website. Webcast replays will be archived for 90 days on the Events page.
Solid’s management will also participate in one-on-one meetings while attending each investor conference. Institutional investors interested in meeting with management during the conference may reach out to their Citi, Cantor, H.C. Wainwright, or Baird representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Solid Biosciences (SLDB) presenting at the Citi Biopharma Conference 2025?
How can investors access Solid Biosciences' (SLDB) conference presentations?
Which conferences will Solid Biosciences (SLDB) attend in September 2025?
How can institutional investors meet with Solid Biosciences' (SLDB) management?
